Saturday 17 October 2026
Export GELS’s income statement to Excel — free account
Gelteq Limited
GELS Healthcare Drug Manufacturers Specialty & Generic
Gelteq Limited’s revenue for fiscal 2025 (year ended June 2025) was $368,500.00, up 282.7% from fiscal 2024.
0.45
0.02
+4.65%
Follow GELS
| Jun '25 | Jun '24 | Jun '23 | Dec '22 | Jun '22 | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | — | — | — | — |
Altman Z-Score |
0.39 | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(2.81) | (1.07) | 2.92 | 2.92 | 2.92 |
Beneish M-Score |
(0.73) | (2.73) | — | — | — |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.38) | 0.00 | 0.00 | 0.00 | 0.00 |
EV/FCF |
(0.38) | 0.00 | 0.00 | 0.00 | 0.00 |
Quick Ratio |
0.14 | 0.05 | 0.55 | 0.55 | 0.55 |
Current Ratio |
0.27 | 0.08 | 0.73 | 0.73 | 0.73 |
Net Debt/EBITDA |
(0.91) | (2.20) | (1.11) | (0.67) | (0.67) |
Debt/Assets |
19.64% | 18.52% | 11.01% | 10.99% | 10.99% |
Debt/Equity |
0.27 | 0.25 | 0.13 | 0.13 | 0.13 |
Asset Turnover |
0.03 | 0.01 | 0.03 | 0.03 | 0.00 |
Operating CF/Net income |
0.83 | 0.30 | 0.51 | 0.00 | 0.00 |
Capex/Depreciation |
(0.53) | (0.12) | (0.06) | — | — |
Interest Coverage |
(2.82) | (4.91) | (7.68) | (7.68) | (7.68) |
| (42.72%) | (20.70%) | (65.48%) | 44.10% | 0.00% | |
| (31.28%) | (16.17%) | (15.59%) | (15.59%) | 0.00% | |
ROIC |
(17.46%) | (9.73%) | (9.35%) | (9.35%) | (9.35%) |
Return on Tangible Assets |
161.70% | 100.00% | 938.53% | 938.53% | 938.53% |
Average Days of Receivables |
294.87 | 454.83 | 203.08 | 203.08 | 203.08 |
Research and Development Expense of Revenue |
110.47% | 187.95% | 107.18% | 107.25% | 107.25% |
Selling, General and Administrative Expense of Revenue |
35.88% | 12.36% | 26.91% | 287.22% | 287.22% |
Intangible Assets out of Total Assets |
0.92 | 0.98 | 0.96 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.04 | 0.01 | 0.05 | 0.00 | 0.00 |
Operating CF per Share |
(0.39) | (0.09) | (0.15) | — | — |
Capex per Share |
(0.04) | (0.01) | (0.01) | — | — |
Free Cash Flow per Share |
(0.43) | (0.10) | (0.16) | — | — |
Cash per Share |
0.02 | 0.00 | 0.03 | 0.00 | 0.00 |
Shareholders Equity per Share |
1.10 | 1.22 | 1.58 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.10 | 1.22 | 1.58 | 0.00 | 0.00 |
Free Cash Flow |
(3.99) | (0.80) | (1.24) | — | — |
Working Capital |
(2.67) | (2.34) | (0.25) | (0.25) | (0.25) |
Capital Expenditures |
(0.42) | (0.10) | (0.05) | — | — |
Net Current Asset Value |
(2.70) | (3.50) | (1.92) | (1.92) | (1.92) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
1.13 | 1.01 | 0.12 | 0.00 | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
76.89 | 72.92 | 0.00 | — | — |
Cash ROIC |
(30.26%) | (6.42%) | (8.57%) | 0.00% | 0.00% |
Accounts Receivable Turnover |
1.76 | 0.55 | 1.80 | 1.80 | 0.00 |
Accounts Payable Turnover |
0.11 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | — | 0.51 | 0.51 | 0.00 |
Average Days of Payables |
1,810.34 | 0.00 | 8,845.43 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | — | 711.14 | 711.14 | 711.14 |
Average Receivables |
0.21 | 0.18 | 0.23 | 0.23 | — |
Average Payables |
0.70 | 0.91 | — | — | — |
Average Inventory |
— | — | 0.06 | 0.06 | — |
Average Assets |
13.76 | 14.38 | 15.14 | 15.14 | — |
Average Common Equity |
10.07 | 11.24 | 3.60 | (5.35) | — |
Columns are period end dates · fundamentals updated 5 Oct 2026